Alan Au
Founder / Managing Partner @ GT Healthcare Capital Partners
Shanghai, China
Alan Au is a Series A investor at GT Healthcare Capital Partners in Shanghai focused on Health Care and Biotechnology. Alan is a veteran in healthcare related investments. He is Founder/Managing Partner at GT Healthcare Partners, an innovative private equity operator focusing on cross border healthcare investments.Alan was senior adviser to Simcere Pharmaceutical Group, a leading pharmaceutical company in China (previously listed on NYSE:SCR, privatized inDec 2013, when Alan was Chairman of the Special Committee on the Board of Directors). He was also a member of the Board, Audit Committee and Compensation Committee of China Nepstar Chain Drugstore Ltd. (NYSE: NPD, privatized in Sep 2016) from 2013 to 2016. Separately, Alan is a member of the Board, Audit Committee and Chairman of Nomination Committee of Cellular BioMedicine Group Inc. (Nasdaq: CBMG), a leader in immune-oncology in China. In addition, he has served as a panel member for the Entrepreneur Support Scheme (ESS Program) of the Innovation and Technology Fund of the Hong Kong SAR Government since 2014.Before that, Alan was Head of Asia Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPOs and M&A in the region between 2011 and 2012. Prior to that, he was Executive Director at JAFCO Asia Investment Group, responsible for healthcare investments in China from 2008 to 2010, and Investment Director at Morningside Group, managing healthcare investments in Asia from 2000 to 2005. From 1995 to 1999, Mr. Au worked at KPMG and KPMG Corporate Finance Ltd., taking care of regional M&A transactions and financial advisory services.Alan is a Certified Public Accountant in the U.S. and holds the Chartered Financial Analyst (CFA) designation. He is an associate member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants. Alan received his Bachelor’s degree in Psychology from the Chinese University of Hong Kong, and a Master’s degree in Management from Columbia Business School in New York.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Alan Au invests in
Stages Alan Au invests in
Countries Alan Au invests in
Investment Focus
Industry
- Health Care 3 (50%)
- Biotechnology 3 (50%)
- Medical Device 3 (50%)
- Medical 1 (17%)
- Diabetes 1 (17%)
Stage
- Series A 2 (33%)
- Seed 1 (17%)
- Series B 1 (17%)
- Series C 1 (17%)
Country
- United States 2 (33%)
- France 1 (17%)
- United Kingdom 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Moon Surgical
|
MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room. | $55.4M / Series B / May 17, 2023 | |
|
Moon Surgical
|
MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room. | $31.3M / Series A / Jun 07, 2022 | |
G.I. Windows
|
G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States. | $16.4M / Series A / Aug 19, 2020 | |
|
G.I. Windows
|
G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States. | $14.6M / Series A / Dec 11, 2019 | |
Potrero Medical
|
Potrero Medical is a predictive health company that is developing the next generation of smart sensors and artificial intelligence. The company is currenly developing a predictive health platform to help medical teams better predict adverse outcomes in critical care settings. It was founded in 2012 and headquartered in Hayward, California. | $26.6M / Series C / Jul 09, 2018 | |
ONI
|
ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers. The Nanoimager, the world's first benchtop sized super-resolution microscope, delivers a step change in usability and precision. This, together with our next-generation consumable products will empower academicresearchers, clinicians and scientists to on a path to discovery.The microscope offers easy access to a range of super-resolution techniques including dSTORM and PALM, as well as smFRET, single-particle tracking and confocal.The company's achievements have been recognised by FastTrack100 who named ONI on their 2018 list of 10 Disruptors to Watch and ONI won Best Business Start-up at the 2018 IOP Awards. More and more life science researchers and pharma companies are taking an interest in ONI and it now has customers using its products in leading laboratories across the globe, including the Universities of Oxford, Cambridge and Harvard.ONI has a restless enthusiasm to make the world a better place. Our ambition is to bring super-resolution fluorescence imaging to a new community of researchers and we are removing barriers to make science more effective, accessible and affordable. Our vision is to accelerate scientific discovery and fight disease by enabling everyone to visualize, understand and share the microscopic details of life. | $3.7M / Seed / Apr 03, 2017 |
Co-Investors
About GT Healthcare Capital Partners
GT Healthcare Capital Partners (“GT Healthcare”) is an Asia-based private investment partnership that specializes in healthcare investments around the globe that aim to change technology landscapes. GT Healthcare intends to provide capital and scale expertise to healthcare businesses in Asia / Greater China.
GT Healthcare Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alan Au
Founder / Managing Partner
|
|||
Jai Hyun Kwon
Venture Partner
|
|||
|
Jason Yeung
Partner
|
|||
Mingxi Li
Partner
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alan Au invest in?
Alan Au invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alan Au last invest?
The most recent investment recorded for Alan Au closed in May 2023. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
